Developing anticancer inhibitors of SIRT1 with RECEPTOR.AI SaaS Platform & More Latest News Here

The SIRT-1: workflow and target features

Radar charts generated by SaaS for selected hit compounds

The results of experimental hit validation and the view of the SaaS platform interface

LONDON, UNITED KINGDOM, August 28, 2022 / — RECEPTOR.AI SaaS platform for drug discovery
Our AI-based drug discovery platform allows virtual screening of billions of chemical compounds in just a few hours against the protein target of interest to find the molecules with the best binding propensity, which are called hits.
The platform is fully automated and combines 40+ integrated AI models with in silico approaches, such as AI-assisted molecular docking. Our technique ensures the identification of high-quality hits, which are favorable candidates for further lead discovery and optimization. Our partnership with top biotech companies allows us to synthesise and experimentally evaluate hit compounds alongside in silico predictions to provide precise and reliable results.

Application of RECEPTOR.AI SaaS platform

The Receptor.AI SaaS platform allows the user to automate small molecule drug discovery workflow. The platform is modular and fully configurable, allowing the construction of a drug discovery R&D pipeline which meets any specific needs of the client (integration of the custom-tuned AI models, incorporation of chemical databases and custom datasets, etc.).

Receptor.AI SaaS platform currently implements the phase of hit discovery and performs two-stage virtual screening: initial screening of the large chemical spaces followed by the precise secondary screening within a preselected pool of compounds. The platform assesses the compounds based on their predicted affinities and pharmacokinetic profiles. The next version of the platform will include lead discovery and lead optimization modules as well.

Initial screening

The system uses ligand-based and two structure-based screening techniques in parallel to get the most reliable virtual screening consensus scores. There are more than 35 pharmacokinetic predictive endpoints to choose from, which could be used to select the molecules with desirable ADMET properties. This allows for a much stricter selection of compounds with high predicted affinity, selectivity and activity while ensuring that they are safe, non-toxic and favorable in terms of ADMET parameters.

Secondary screening

The system performs fully automated AI-assisted molecular docking of the molecules selected in the initial screening phase. It prioritises the most promising candidates for further synthesis and biological validation. At this stage, the proteome-wide binding profiles are also analyzed to identify possible off-target interactions and to get a reliable selectivity prediction.

Technological innovations of Receptor.AI allowed finding novel inhibitors of BRD4 in less than 6 weeks, including their synthesis and biological validation.

Enamine stock database of 3.5M high-quality drug-like molecules was screened using the Drug-Target Interactions (DTI) models integrated into the SaaS platform. After that, our proprietary ADME-Tox models were used to narrow the results with the following ADMET endpoints: Ames mutagenicity, carcinogenicity (ISF and OSF), DILI, hERG blocking, Bioavailability, HIA, BBB crossing, PPB, P-gp and CYP1A2 , CYP2C9, CYP2C19, CYP2D6, CYP3A4 substrate-like binding/inhibition. 21556 best-ranked compounds were advanced to the secondary screening phase, where they were evaluated by Molecular Docking with a custom-tuned AI-based scoring function.

Predicted ADMET profiles and activities of experimentally validated hit compounds

RAIST10058. This compound has shown an outstanding nanomolar activity (90 nM) and high selectivity, which makes it de facto a lead compound. Moreover, our multi-task ADMET model predicted a high propensity for BBB permeation for this compound, low hepatotoxicity and an acceptable plasma protein binding rate. The lack of predicted degradation by cytochromes needs further optimization, but this is not critical in the hit discovery stage.

RAIST10044. This compound has also shown good experimental activity. It has a promising bioavailability/toxicity profile and prospects of being biodegradable by cytochromes. But relatively high hepatotoxicity and PPB still need optimization.

RAIST10081. This compound has good experimental activity and a good toxicity profile, but it is less biodegradable by cytochromes in comparison to the RAIST10044. It also has higher PPB and possesses a moderate risk of DILI induction.

RAIST10086. This compound has good experimental activity and a good toxicity profile, but it is even less biodegradable by cytochromes, lacks the BBB permeation, possesses a moderate risk of DILI induction and has a somewhat questionable distribution due to relatively high PPB.

RAIST10104. This compound has shown decent experimental activity. It belongs to a novel class of compounds which were previously unknown as SIRT1 inhibitors. It has a good toxicity profile, but there are questions concerning its cytochrome safety, DILI and PPB. However, these disadvantages are acceptable on the hit discovery stage, taking into account its unprecedented novelty.

Details of experimental validation

100 best-ranked hit compounds were experimentally validated by our partners. 5 of them have shown high affinity to SIRT1. These compounds are currently subject to in-depth experimental validation followed by hit-to-lead and lead optimization stages.

No alt text provided for this image

Alan Nafiieva
+49 1517 2837276
[email protected]
Visit us on social media:

Developing anticancer inhibitors of SIRT1 with RECEPTOR.AI SaaS Platform & Latest News Update

I have tried to give all kinds of news to all of you latest news today 2022 through this website and you are going to like all this news very much because all the news we always give in this news is always there. It is on trending topic and whatever the latest news was

it was always our effort to reach you that you keep getting the Electricity News, Degree News, Donate News, Bitcoin News, Trading News, Real Estate News, Gaming News, Trending News, Digital Marketing, Telecom News, Beauty News, Banking News, Travel News, Health news, Cryptocurrency News, Claim News latest news and you always keep getting the information of news through us for free and also tell you people. Give that whatever information related to other types of news will be

Developing anticancer inhibitors of SIRT1 with RECEPTOR.AI SaaS Platform & More Live News

All this news that I have made and shared for you people, you will like it very much and in it we keep bringing topics for you people like every time so that you keep getting news information like trending topics and you It is our goal to be able to get

all kinds of news without going through us so that we can reach you the latest and best news for free so that you can move ahead further by getting the information of that news together with you. Later on, we will continue

to give information about more today world news update types of latest news through posts on our website so that you always keep moving forward in that news and whatever kind of information will be there, it will definitely be conveyed to you people.

Developing anticancer inhibitors of SIRT1 with RECEPTOR.AI SaaS Platform & More News Today

All this news that I have brought up to you or will be the most different and best news that you people are not going to get anywhere, along with the information Trending News, Breaking News, Health News, Science News, Sports News, Entertainment News, Technology News, Business News, World News of this made available to all of you so that you are always connected with the news, stay ahead in the matter and keep getting today news all types of news for free till today so that you can get the news by getting it. Always take two steps forward

Credit Goes To News Website – This Original Content Owner News Website . This Is Not My Content So If You Want To Read Original Content You Can Follow Below Links

Get Original Links Here🡽

Leave a Comment

Your email address will not be published. Required fields are marked *